Compare NYAX & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYAX | VERA |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.0B |
| IPO Year | 2022 | 2021 |
| Metric | NYAX | VERA |
|---|---|---|
| Price | $51.63 | $34.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $49.50 | ★ $81.30 |
| AVG Volume (30 Days) | 30.4K | ★ 1.8M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.66 | N/A |
| Revenue Next Year | $21.70 | $472.48 |
| P/E Ratio | $89.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.17 | $22.72 |
| 52 Week High | $76.86 | $56.05 |
| Indicator | NYAX | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 39.46 | 50.01 |
| Support Level | $43.06 | $33.43 |
| Resistance Level | $55.40 | $37.13 |
| Average True Range (ATR) | 1.08 | 1.67 |
| MACD | 0.59 | 0.29 |
| Stochastic Oscillator | 43.63 | 56.41 |
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It unifies payments, operations management, and customer engagement tools into a powerful, adaptable platform for modern commerce. It provides solutions that empower businesses to enhance customer experience, accept cashless payments, and manage their operations with a robust Internet of Things (IoT) software platform, helping achieve long-term growth. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.